Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis

被引:56
作者
Nagasaka, Takeshi [1 ,2 ]
Goel, Ajay [1 ]
Notohara, Kenji [3 ]
Takahata, Takaomi [2 ]
Sasamoto, Hiromi [2 ]
Uchida, Takuyuki [2 ]
Nishida, Naoshi [1 ]
Tanaka, Noriaki [2 ]
Boland, Clement Richard [1 ]
Matsubara, Nagahide [2 ]
机构
[1] Baylor Univ, Med Ctr, Div Gastroenterol, GI Canc Res Lab, Dallas, TX 75246 USA
[2] Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Surg & Surg Oncol, Okayama 7008558, Japan
[3] Okayama Univ, Grad Sch Med & Dent, Dept Pathol Res, Okayama 7008558, Japan
关键词
O-6 -methylguanine-DNA methyltransferase; KRAS mutations; promoter methylation; colorectal cancer; adenomatous polyps;
D O I
10.1002/ijc.23398
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O-6 -methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene which is frequently methylated in colorectal cancer (CRC). However, it remains controversial whether methylation of specific CpG sequences within MGMT promoter leads to loss of its protein expression, and if MGMT methylation correlates with G to A transition mutations in KRAS. Two methylation sensitive regions (Mp and Eh region) of MGMT promoter were investigated in 593 specimens of colorectal tissue: 233 CRCs, 104 adenomatous polyps (AP), 220 normal colonic mucosa from CRC patients (N-C) and 36 normal colonic mucosa specimens obtained from subjects without colorectal neoplasia (N-N) by combined bisulfite restriction analysis (COBRA). The region-specific methylation data were compared to the MGMT protein expression, spectrum of KRAS mutations and other clinical features. Extensive (including both Mp and Eh) and partial (either Mp or Eh) MGMT methylation were found in 24.5% and 11.6% of CRCs, 3.8% and 27.9% of APs, 0.5% and 7.7% of C-Ns and 2.8% and 2.8% of N-Ns, respectively. Extensive methylation of MGMT promoter was primarily present in CRCs while partial methylation was common in APs. Extensive methylation of MGMT promoter was associated with loss/reduced protein expression (p < 0.0001), as well as with G to A mutations in KRAS (p = 0.0017). We herein provide first evidence that extensive methylation of MGMT promoter region is essential for methylation-induced silencing of this gene. Our data suggest that MGMT methylation may evolve and spread throughout the promoter in a stepwise manner as the colonic epithelial cells progress through the classical-adenoma-cancer multistep cascade. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2429 / 2436
页数:8
相关论文
共 50 条
  • [21] Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis
    Zheng, Chen-guo
    Jin, Chun
    Ye, Le-chi
    Chen, Nian-zhao
    Chen, Zong-Jing
    TUMOR BIOLOGY, 2015, 36 (08) : 5839 - 5848
  • [22] Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis
    Zhong, Yu
    Huang, Yongsheng
    Huang, Yan
    Zhang, Tianbao
    Ma, Chengying
    Zhang, Shuyong
    Fan, Weiwei
    Chen, Hongyan
    Qian, Ji
    Lu, Daru
    MUTAGENESIS, 2010, 25 (01) : 83 - 95
  • [23] Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers
    Matsukura, S
    Miyazaki, K
    Yakushiji, H
    Ogawa, A
    Harimaya, K
    Nakabeppu, Y
    Sekiguchi, M
    ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (10) : 807 - 816
  • [24] Detection of O6-methylguanine-DNA methyltransferase gene methylation status in IDH-wild type glioblastomas using methylation-specific qPCR: a first report from Morocco
    Oukhdouch, Anass
    Hakmaoui, Abdelmalek
    Zinbi, Basma
    Sellami, Souad
    Hayat, Bouighajd
    Rais, Hanane
    PAN AFRICAN MEDICAL JOURNAL, 2024, 49
  • [25] Repair gene O6-methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation
    Aasland, Dorthe
    Reich, Thomas R.
    Tomicic, Maja T.
    Switzeny, Olivier J.
    Kaina, Bernd
    Christmann, Markus
    JOURNAL OF NEUROCHEMISTRY, 2018, 144 (02) : 139 - 151
  • [26] Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma
    Kokunai, Yasuhito
    Tsuji, Motomu
    Ito, Yuko
    Kurokawa, Teruo
    Otsuki, Yoshinori
    Moriwaki, Shinichi
    MEDICAL MOLECULAR MORPHOLOGY, 2014, 47 (01) : 8 - 13
  • [27] Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma
    Ge, Nan
    Guo, Liqiang
    Zhang, Jie
    Lin, Zhaomin
    Li, Yan
    Liu, Yuqiang
    Kong, Feng
    Fang, Xiaolei
    Zhao, Shengtian
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (09) : 860 - 866
  • [28] Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression
    Rahman, Wan Faiziah Wan Abdul
    Ab Rahman, Khairul Shakir
    Nafi, Siti Norasikin Mohd
    Fauzi, Mohd Hashairi
    Jaafar, Hasnan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 6095 - 6106
  • [29] Enhancing temozolomide antiglioma response by inhibiting O6-methylguanine-DNA methyltransferase with selected phytochemicals: in silico and in vitro approach
    Vibhavari, R. J. A.
    Rao, Vanishree
    Cheruku, Sri Pragnya
    Kumar, B. Harish
    Maity, Swastika
    Nandakumar, Krishnadas
    Kumar, Lalit
    Mehta, Chetan Hasmukh
    Nayak, Usha
    Chamallamudi, Mallikarjuna Rao
    Kumar, Nitesh
    3 BIOTECH, 2023, 13 (12)
  • [30] O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)
    Lemelin, Annie
    Barritault, Marc
    Hervieu, Valerie
    Payen, Lea
    Peron, Julien
    Couvelard, Anne
    Cros, Jerome
    Scoazec, Jean-Yves
    Bin, Sylvie
    Villeneuve, Laurent
    Lombard-Bohas, Catherine
    Walter, Thomas
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (04) : 595 - 599